ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.102,15
0,75%
S&P 500
5.930,85
1,09%
US Dollar vs BRL
6,086
0,00%
Bitcoin
96.492,94
-0,73%
Brent Oil
72,72
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Eton Pharmaceuticals Inc (ETON)

  7. Eton Pharmaceuticals Inc (ETON) Notícias

ETON

Eton Pharmaceuticals (ETON)

Eton Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ETON
DataHoraFonteTítuloCódigoCompanhia
20/12/202409:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ETONEton Pharmaceuticals Inc
20/12/202408:50GlobeNewswire Inc.Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)NASDAQ:ETONEton Pharmaceuticals Inc
17/12/202408:50GlobeNewswire Inc.Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical TrialNASDAQ:ETONEton Pharmaceuticals Inc
12/12/202418:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ETONEton Pharmaceuticals Inc
09/12/202419:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ETONEton Pharmaceuticals Inc
03/12/202408:50GlobeNewswire Inc.Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial OfficerNASDAQ:ETONEton Pharmaceuticals Inc
25/11/202408:50GlobeNewswire Inc.Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)NASDAQ:ETONEton Pharmaceuticals Inc
12/11/202418:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ETONEton Pharmaceuticals Inc
12/11/202418:01GlobeNewswire Inc.Eton Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
07/11/202409:00GlobeNewswire Inc.Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)NASDAQ:ETONEton Pharmaceuticals Inc
06/11/202418:30GlobeNewswire Inc.Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024NASDAQ:ETONEton Pharmaceuticals Inc
04/10/202417:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ETONEton Pharmaceuticals Inc
03/10/202407:30GlobeNewswire Inc.Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from IpsenNASDAQ:ETONEton Pharmaceuticals Inc
22/08/202417:30GlobeNewswire Inc.Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ETONEton Pharmaceuticals Inc
08/08/202417:01GlobeNewswire Inc.Eton Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
02/08/202417:16Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ETONEton Pharmaceuticals Inc
30/07/202418:30GlobeNewswire Inc.Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024NASDAQ:ETONEton Pharmaceuticals Inc
15/07/202417:05GlobeNewswire Inc.Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)NASDAQ:ETONEton Pharmaceuticals Inc
09/05/202417:01GlobeNewswire Inc.Eton Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
01/05/202417:05GlobeNewswire Inc.Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences ConferenceNASDAQ:ETONEton Pharmaceuticals Inc
30/04/202408:00GlobeNewswire Inc.Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)NASDAQ:ETONEton Pharmaceuticals Inc
29/04/202417:30GlobeNewswire Inc.Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:ETONEton Pharmaceuticals Inc
22/03/202403:00GlobeNewswire Inc.Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for PhenylketonuriaNASDAQ:ETONEton Pharmaceuticals Inc
14/03/202417:01GlobeNewswire Inc.Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
29/02/202418:01GlobeNewswire Inc.Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024NASDAQ:ETONEton Pharmaceuticals Inc
21/02/202408:50GlobeNewswire Inc.Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid FormulationNASDAQ:ETONEton Pharmaceuticals Inc
02/02/202408:50GlobeNewswire Inc.Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone CapsulesNASDAQ:ETONEton Pharmaceuticals Inc
09/11/202318:01GlobeNewswire Inc.Eton Pharmaceuticals Reports Third Quarter 2023 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
30/10/202307:50GlobeNewswire Inc.Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023NASDAQ:ETONEton Pharmaceuticals Inc
18/10/202309:00PR Newswire (US)SWK Holdings Highlights Recent Achievements and Provides Portfolio UpdateNASDAQ:ETONEton Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ETON

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados